Capromab pendetide. A review of its use as an imaging agent in prostate cancer.
Identifieur interne : 003F27 ( Main/Exploration ); précédent : 003F26; suivant : 003F28Capromab pendetide. A review of its use as an imaging agent in prostate cancer.
Auteurs : RBID : pubmed:9571393English descriptors
- KwdEn :
- Antibodies, Monoclonal (administration & dosage), Antibodies, Monoclonal (diagnostic use), Antibodies, Monoclonal (pharmacokinetics), Antibodies, Monoclonal (pharmacology), Clinical Trials as Topic, Humans, Immunoconjugates (administration & dosage), Immunoconjugates (diagnostic use), Immunoconjugates (pharmacokinetics), Immunoconjugates (pharmacology), Male, Prostatic Neoplasms (radionuclide imaging), Radiopharmaceuticals.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Immunoconjugates.
- chemical , diagnostic use : Antibodies, Monoclonal, Immunoconjugates.
- chemical , pharmacokinetics : Antibodies, Monoclonal, Immunoconjugates.
- chemical , pharmacology : Antibodies, Monoclonal, Immunoconjugates.
- radionuclide imaging : Prostatic Neoplasms.
- Clinical Trials as Topic, Humans, Male, Radiopharmaceuticals.
Abstract
Capromab pendetide, radiolabelled with indium-111, is a radioimmunoscintigraphic imaging agent used in patients with prostate cancer. It consists of a murine monoclonal antibody (7E11-C5.3) covalently jointed to a linker-chelator molecule. 7E11-C5.3 is thought to be directed against the intracellular domain of human prostate-specific membrane antigen (PSMA), a transmembrane glycoprotein expressed by prostate epithelial cells. The diagnostic utility of capromab pendetide has been investigated in 2 distinct patient groups. In patients with untreated prostate cancer at high risk for pelvic lymph node metastases, capromab pendetide imaging had respective sensitivities and specificities of 52 and 96% in 1 study and 62 and 72% in another, as confirmed by pelvic lymph node dissection biopsy results. In patients with suspected occult recurrent or residual disease after prostatectomy, capromab pendetide had respective sensitivities and specificities of 49 and 71% in 1 study and 77 and 35% in another for detection of cancer in the prostate bed. Almost half of these patients also had evidence of lesions outside the prostate fossa (usually in the pelvic and abdominal lymph nodes) according to immunoscintigraphic scans, but too few cases were confirmed to allow an evaluation of capromab pendetide. Four per cent of patients who received single doses of capromab pendetide experienced adverse events. Elevated bilirubin levels, hypertension and hypotension each affected 1% of patients and elevated liver enzymes and injection site reactions < 1% of patients. Detectable human anti-mouse antibodies were reported in 8% of patients after a single dose of capromab pendetide and in 19% of patients after repeat infusions.
PubMed: 9571393
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Capromab pendetide. A review of its use as an imaging agent in prostate cancer.</title><author><name sortKey="Lamb, H M" uniqKey="Lamb H">H M Lamb</name><affiliation wicri:level="1"><nlm:affiliation>Adis International Limited, Auckland, New Zealand. demail@adis.co.nz</nlm:affiliation><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Adis International Limited, Auckland</wicri:regionArea></affiliation></author><author><name sortKey="Faulds, D" uniqKey="Faulds D">D Faulds</name></author></titleStmt><publicationStmt><date when="1998">1998</date><idno type="RBID">pubmed:9571393</idno><idno type="pmid">9571393</idno><idno type="wicri:Area/Main/Corpus">004142</idno><idno type="wicri:Area/Main/Curation">004142</idno><idno type="wicri:Area/Main/Exploration">003F27</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal (administration & dosage)</term><term>Antibodies, Monoclonal (diagnostic use)</term><term>Antibodies, Monoclonal (pharmacokinetics)</term><term>Antibodies, Monoclonal (pharmacology)</term><term>Clinical Trials as Topic</term><term>Humans</term><term>Immunoconjugates (administration & dosage)</term><term>Immunoconjugates (diagnostic use)</term><term>Immunoconjugates (pharmacokinetics)</term><term>Immunoconjugates (pharmacology)</term><term>Male</term><term>Prostatic Neoplasms (radionuclide imaging)</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Immunoconjugates</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Immunoconjugates</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Immunoconjugates</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Immunoconjugates</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Prostatic Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term><term>Humans</term><term>Male</term><term>Radiopharmaceuticals</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Capromab pendetide, radiolabelled with indium-111, is a radioimmunoscintigraphic imaging agent used in patients with prostate cancer. It consists of a murine monoclonal antibody (7E11-C5.3) covalently jointed to a linker-chelator molecule. 7E11-C5.3 is thought to be directed against the intracellular domain of human prostate-specific membrane antigen (PSMA), a transmembrane glycoprotein expressed by prostate epithelial cells. The diagnostic utility of capromab pendetide has been investigated in 2 distinct patient groups. In patients with untreated prostate cancer at high risk for pelvic lymph node metastases, capromab pendetide imaging had respective sensitivities and specificities of 52 and 96% in 1 study and 62 and 72% in another, as confirmed by pelvic lymph node dissection biopsy results. In patients with suspected occult recurrent or residual disease after prostatectomy, capromab pendetide had respective sensitivities and specificities of 49 and 71% in 1 study and 77 and 35% in another for detection of cancer in the prostate bed. Almost half of these patients also had evidence of lesions outside the prostate fossa (usually in the pelvic and abdominal lymph nodes) according to immunoscintigraphic scans, but too few cases were confirmed to allow an evaluation of capromab pendetide. Four per cent of patients who received single doses of capromab pendetide experienced adverse events. Elevated bilirubin levels, hypertension and hypotension each affected 1% of patients and elevated liver enzymes and injection site reactions < 1% of patients. Detectable human anti-mouse antibodies were reported in 8% of patients after a single dose of capromab pendetide and in 19% of patients after repeat infusions.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">9571393</PMID><DateCreated><Year>1998</Year><Month>06</Month><Day>05</Day></DateCreated><DateCompleted><Year>1998</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2013</Year><Month>05</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1170-229X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>1998</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Drugs & aging</Title><ISOAbbreviation>Drugs Aging</ISOAbbreviation></Journal><ArticleTitle>Capromab pendetide. A review of its use as an imaging agent in prostate cancer.</ArticleTitle><Pagination><MedlinePgn>293-304</MedlinePgn></Pagination><Abstract><AbstractText Label="UNLABELLED">Capromab pendetide, radiolabelled with indium-111, is a radioimmunoscintigraphic imaging agent used in patients with prostate cancer. It consists of a murine monoclonal antibody (7E11-C5.3) covalently jointed to a linker-chelator molecule. 7E11-C5.3 is thought to be directed against the intracellular domain of human prostate-specific membrane antigen (PSMA), a transmembrane glycoprotein expressed by prostate epithelial cells. The diagnostic utility of capromab pendetide has been investigated in 2 distinct patient groups. In patients with untreated prostate cancer at high risk for pelvic lymph node metastases, capromab pendetide imaging had respective sensitivities and specificities of 52 and 96% in 1 study and 62 and 72% in another, as confirmed by pelvic lymph node dissection biopsy results. In patients with suspected occult recurrent or residual disease after prostatectomy, capromab pendetide had respective sensitivities and specificities of 49 and 71% in 1 study and 77 and 35% in another for detection of cancer in the prostate bed. Almost half of these patients also had evidence of lesions outside the prostate fossa (usually in the pelvic and abdominal lymph nodes) according to immunoscintigraphic scans, but too few cases were confirmed to allow an evaluation of capromab pendetide. Four per cent of patients who received single doses of capromab pendetide experienced adverse events. Elevated bilirubin levels, hypertension and hypotension each affected 1% of patients and elevated liver enzymes and injection site reactions < 1% of patients. Detectable human anti-mouse antibodies were reported in 8% of patients after a single dose of capromab pendetide and in 19% of patients after repeat infusions.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Capromab pendetide offers improved sensitivity in the detection of prostate cancer over other noninvasive techniques. When used in conjunction with other techniques, it offers the possibility of defining the extent of localised and metastatic disease, thereby refining patient management.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lamb</LastName><ForeName>H M</ForeName><Initials>HM</Initials><Affiliation>Adis International Limited, Auckland, New Zealand. demail@adis.co.nz</Affiliation></Author><Author ValidYN="Y"><LastName>Faulds</LastName><ForeName>D</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType><PublicationType>Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>NEW ZEALAND</Country><MedlineTA>Drugs Aging</MedlineTA><NlmUniqueID>9102074</NlmUniqueID><ISSNLinking>1170-229X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Immunoconjugates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>145464-28-4</RegistryNumber><NameOfSubstance>Capromab Pendetide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName MajorTopicYN="N">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName><QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Immunoconjugates</DescriptorName><QualifierName MajorTopicYN="N">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName><QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Prostatic Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>52</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>5</Month><Day>8</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>5</Month><Day>8</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9571393</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003F27 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003F27 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:9571393
|texte= Capromab pendetide. A review of its use as an imaging agent in prostate cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:9571393" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |